Iron-polymaltose-complex (IPC) is a pharmaceutical compound used as an iron supplement in the treatment of iron deficiency anemia. IPC is a complex of iron (III) with a carbohydrate polymer, typically maltose or a maltodextrin, which allows for improved absorption and bioavailability of iron in the body. West Bengal Chemical Industries Ltd is one of the top Iron-polymaltose-complex manufacturer companies in India.
IPC is typically represented by the chemical formula Fe(OH)x[(C6H10O5)y]n, where x, y, and n can vary depending on the specific product.
Some synonyms for IPC include iron-maltose complex, ferric-maltol complex, and iron-hydroxide-polymaltose complex.
IPC is characterized by its ability to provide an easily absorbed form of iron that is less likely to cause gastrointestinal side effects compared to other forms of iron supplements, such as ferrous sulfate. It is also known for its relatively low toxicity compared to other iron compounds. IPC is typically administered orally or intravenously, depending on the patient’s needs and medical history.
Molecular Formula – C24H44FeO25
Molecular Weight – 203.96 gm/mol
CAS No – 20150-34-9
Shelf Life – 36 months
HSN Code – 2821.1020
Packing Size – 20 kg in (sterile) HDPE drum
Storage Condition – Keep Well Closed, protected against light, dry and at room temperature
Additional Info – 1. Available as powder, DC grade & injectable grade
|1.||Description||Brown to deep brown colour free flowing powder.|
|2.||Solubility||NLT 5 g sample dissolved in 100 ml water|
|3.||Identification||Positive for Iron & Maltose.|
|4.||pH (of 5% w/v aqueous solution)||5.5 – 7.5|
|5.||Loss on Drying (at 105°C for 4 hrs.)||NMT 8.0% w/w|
|6.||Arsenic||NMT 3.0 ppm|
|7.||Heavy Metals (as Lead)||NMT 10.0 ppm|
|9.||Zinc||NMT 150.0 ppm|
|10.||Free Iron||Should be absent|
|11.||Chloride (On Dried Basis)||NMT 3.0% w/w|
|12.||Carbohydrates (Polymaltose)(On Dried Basis)||25.0% – 50.0% w/w|
|13.||Assay For Elemental Iron (On Dried Basis)||26.0% – 36.0% w/w|
|14.||Total Microbial Count||Less than 1000 cfu/gm|
|15.||Total Combined Yeasts & Mould||Less than 100 cfu/gm|
Treatment of iron-deficiency anemia: IPC is a commonly used iron supplement for the treatment of iron-deficiency anemia. It is effective in increasing hemoglobin levels and replenishing iron stores in the body.
Treatment of chronic kidney disease: Patients with chronic kidney disease often have low levels of iron, and IPC is used to treat this condition. It is effective in improving hemoglobin levels and reducing the need for blood transfusions.
Treatment of pregnancy-related anemia: Pregnant women often experience anemia due to increased iron requirements. IPC is a safe and effective treatment option for pregnancy-related anemia.
Iron supplementation in pediatric patients: IPC is used to provide iron supplementation to infants and children. It is effective in improving iron levels and preventing iron-deficiency anemia.
As a food fortifier: IPC can also be used as a food fortifier to increase the iron content in food products. This is particularly useful in developing countries where iron deficiency is common.
Cosmetic applications: IPC is sometimes used in cosmetic products to improve the appearance of skin and hair. It is believed to have anti-oxidant and anti-inflammatory properties that can help to reduce the signs of aging.
Abstract Background: Iron Deficiency Anemia (IDA) is a major public health problem worldwide. Iron Bisglycinate Chelate (FeBC) and polymaltose iron (FeP) are used for the treatment of IDA and exhibit good tolerability with a low incidence of adverse effects. However,...Read more
Summary: Iron Deficiency Anemia (IDA) is a prevalent global health issue. Two commonly used treatments for IDA are Iron Bisglycinate Chelate (FeBC) and polymaltose iron (FeP). These treatments are well-tolerated by patients and have a low occurrence of adverse effects....Read more
Abstract The following review of iron(III)-hydroxide polymaltose complex (IPC, Maltofer) shows that iron is significantly bioavailable after oral administration, especially in iron-deficient subjects. Numerous clinical trials in men, women, children and infants have shown that IPC is effective in treating...Read more
Abstract Background: Iron deficiency anemia (IDA) is commonly treated with iron formulations. Despite the expanding acceptance of iron polymaltose complex (IPC) among clinicians, there is sparse and contradictory evidence regarding its efficacy in the management of IDA in children. This...Read more